There is now good evidence that cytokines contribute to the regulation of tumor growth. The cytokinedriven modulation of tumor growth was investigated during the progression of a hepatocellular carcinoma (HCC) in SV40 large T tumor antigen transgenic mice. In vivo, an increased rate of liver growth correlated with increased transforming growth factor (TGF)-β1 mRNA expression, while the greatest amounts of tumor necrosis factor (TNF)-α mRNA were detected earlier during tumor development. Conversely, no particular alteration of IL-1α, IL-1β, IL-6, IL-2, IL-4 and IFN-γ mRNA production could be reported. In vitro, hepatocyte-like tumor cell lines established at two stages, either before or after HCC differentiation, were characterized. The early-stage-derived cell line produced TNF-α mRNA, but had barely detectable expression of TGF-β1 mRNA, while later-stagederived cell lines showed the reciprocal pattern. All cell lines displayed a lack of sensitivity to TNF-α, although some degree of sensitivity to TNF-α could be observed in the presence of actinomycin-D or after treatment with IFN-γ. The early-stage-derived cell line was sensitive to the growth inhibitory effects of TGF-β1, but late-stage-derived tumor cell lines displayed a loss of sensitivity to TGF-β1 which correlated with the increased expression of TGF-β1 mRNA. Altogether, this suggests that tumor cells contribute to the discrete TNF-α and TGF-β1 expression patterns during HCC progression. This model of HCC could be of valuable interest to assess the impact of various immunotherapeutic strategies on modulation of tumor growth.
Introduction
The contributions of specific growth factors and cytokines to the development and progression of cancer is well documented. Local cytokine production is thought to play a central role in regulating the recruitment of tumor-associated inflammatory cells (1) , in the induction of angiogenesis (2) and in the direct modulation of tumor cell proliferation (3) . Hepatocellular carcinoma (HCC) is a frequent malignancy in man with poor prognosis. Some data have suggested that tumor growth and In vitro and in vivo studies have demonstrated that tumor cells can produce a wide spectrum of cytokines depending on tumor location or etiology (6, 7) . The cytokines produced by tumor cells have autocrine and/or paracrine stimulatory effects on tumor growth (8, 9) . Little is known about the evolution in vivo of cytokine-producing cells during tumor development. Tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β are two relevant growth regulators, they are both proinflammatory cytokines with a broad spectrum of physiological functions, including the regulation of cell cycle. TNF-α was initially reported to induce hemorrhagic necrosis of some tumors in murine models of tumor transplantation and lysis of certain tumor cells (10) . However, susceptibility to TNF-α is not a common phenotype neither for tumor cells nor for normal cells, including hepatocytes (11, 12) . Furthermore, TNF-α can also act as a growth stimulator for certain tumor cells (13) . TGF-β is produced by numerous tumor cells and also by many normal tissues (14) . This cytokine is a potent negative growth regulator for a wide spectrum of cells and tissue types, including hepatocytes (15) . However, TGF-β also promotes angiogenesis and connective tissue development during oncogenesis (16) , thus indirectly favoring tumor growth. Dysregulated production of TNF-α and TGF-β have been reported during the development of neoplasic tissues (17, 18) . Furthermore, it has been observed in vitro that some tumor cells can become resistant to growthmodulator cytokines at advanced stages of tumorigenesis (3) . The changes underlying this conversion of tumor cells remain largely unknown. In vitro studies have demonstrated that direct treatment of some tumor cells by growth factors could be associated to the selection of resistant tumor cells (19) .
New insights into several aspects of the nature of oncogenesis and tumor growth in vivo have been gained by the development of transgenic mice in which oncogenes are targeted to specific tissues (20) . Transgenic models are also suitable for establishing tumor-derived cell lines, so providing valuable tools for in vitro studies on the responses of tumor cells to various factors. We have chosen transgenic mice expressing the simian virus 40 large T antigen (SV40-T antigen) targeted to the liver (21) to define a model for analyzing in vivo interconnections between the tumor and its environment. The SV40-T antigen is thought to induce neoplasic transformation by interacting directly with cellular proteins that normally regulate cell proliferation, such as Rb, p107 and p53 (22, 23) . The evolution of HCC was analyzed by monitoring various cytokine gene expression in the liver with reference to tumor growth in transgenic mice, using a sensitive RT-PCR system. Critical phases of HCC progression were identified, at which the kinetics of tumor growth and TNF-α and TGF-β1 gene expression were modified. In vitro, we assessed the relative contribution of hepatocyte tumor cells to discrete cytokine gene expression patterns within a whole organ harboring a progressive tumor. This was done by characterizing hepatocyte-like tumor cell lines derived from transgenic mice (24, 25) at two stages of tumor development. The differential properties of the hepatocyte tumor cell lines were analyzed for TNF-α and TGF-β1 gene expression, and for their susceptibility to these growth modulators.
Methods

Mice
Mice of the inbred strain C57BL/6 were obtained from Iffa Credo (Marnes-la-Coquette, France). The transgenic mouse lineage ASV-B used in this study was provided by P. Briand (U380 INSERM, Paris, France) and was extensively backcrossed with C57BL/6 mice. The expression of SV40 early region was targeted to the liver in transgenic mice using the regulatory region of antithrombin III (ATIII) as previously described (21) . The F 1 founders (C57BL/6ϫDBA/2) ASV-B mice had the ATIII-TSV40 transgene inserted on the Y chromosome. Mice of the ASV-B lineage succumbed to HCC before 250 days of age.
Cell lines AT1-F8, AT2 and AT3-F hepatocyte-like cell lines (H-2 dϫb ) were isolated from fully developed HCC of 6-month-old transgenic mice harboring the ATIII-TSV40 transgene (24, 25) . The AT1-F8, AT2 and AT3-F cell lines were heterogeneous with regard to certain criteria of hepatocyte cell differentiation, as assessed by the expression of genes specific for the hepatic phenotype (24, 25) . Notably, the AT2 cells had the least differentiated hepatocyte-like phenotype. The hepatocyte-like cell line ATF7 was a gift from D. Farge (U380 INSERM, Paris, France) and was derived from the liver of a 90-day-old ASV-B transgenic mouse, corresponding to an early stage of tumor development (nodules of~1 mm diameter). These tumor cell lines were cultured in DMEM-F12 medium (Gibco/BRL Life Technologies, Gaithersburg, MD) supplemented with antibiotics, 0.1 mM insulin, 2 mM glutamine, 1 mM dexamethasone, 1 mM 3,3Ј,5-tri-iodo D-thyronine (Sigma, St Louis, MO) and 5% (v/v) FCS (Boehringer Mannheim, Indianapolis, IN).
Tumor cell growth assay
The effects of cytokines on tumor cell growth were examined using tumor cells harvested with PBS, 0.05% trypsin and 0.02% EDTA (Gibco/BRL Life Technologies) from subconfluent cultures. The cells were washed twice and seeded into 96-well flat-bottom microplates (Costar, Cambridge, MA) at 5000 cells in 100 µl culture medium. Mouse recombinant IFN-γ (PharMingen, San Diego, CA) was added in 50 µl medium, to give a final concentration of 0.5-100 U/ml. Mouse recombinant TNF-α (PharMingen) was added in 50 µl medium to a final concentration of 0.2-50 ng/ml, with or without actinomycin D (ActD; Sigma). Human recombinant TGF-β1 (Genzyme, Cambridge, MA) was added in 50 µl medium, to a final concentration of 0.03-4 U/ml. The cells were incubated with each cytokine or cytokine combination (treated cells) or without cytokines (controls) for 24, 48 or 72 h. MTT (10 µl, 5 mg/ml; Sigma) was then added to each well and the plates were incubated for another 4 h at 37°C. MTT is a pale yellow substrate that produces a dark blue formazan product when incubated with live cells. The blue crystals of formazan were dissolved in 100 µl aqueous 16% SDS and 40% N-N dimethyl formamide (Sigma). The plates were read in a MR500 microplate reader (Dynatech, Chantilly, VA) at 540 nm.
RNA isolation and cDNA synthesis
Mice were killed and their livers collected. The livers were minced finely and RNA was isolated by the method of Chomczynski and Sacchi (26) . Briefly, liver samples were homogenized in lysis buffer (4 M guanidium isothiocyanate, 25 mM sodium citrate, pH 7, 0.5% N-laurolsarcosine; Sigma). Total RNA was prepared by phenol-chloroform extraction and ethanol precipitation. A round of PCR was executed on the total RNA preparations to check that the samples were free of genomic DNA. RNA preparations from tumor cell lines were treated in the same way. cDNA was synthesized by placing 2 mg total RNA at 37°C in 20 µl of 1ϫreaction buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol), containing 200 nmol of each deoxynucleoside triphosphate (Pharmacia, Piscataway, NJ), 100 ng oligodT [12] [13] [14] [15] [16] [17] [18] primer (Pharmacia) and 60 U MMLV reverse transcriptase (Gibco/BRL Life Technologies).
PCR
PCR was performed in a 50 µl reaction mixture containing PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 0.1% Triton X-100), 800 µM dNTP mixture, 0.32 nM 5Ј and 3Ј oligonucleotide primers, and 1 U Taq polymerase (Promega, Madison, WI). The primer sequences were: β 2 -microglobulin (β 2 m)-sense (S) 5Ј-TGACCGGCTTGTATGCTA-TC-3Ј; β 2 m-anti-sense (AS) 5Ј-CAGTGTGAGCCAGGATATT-AG-3Ј; IL-1α-S 5Ј-CAGTTCTGCCATTGACCATC-3Ј; IL-1α-AS 5Ј-TCTCACTGAAACTCAGCCGT-3Ј; IL-1β-S 5Ј-TTGACGGA-CCCCAAAAGATG-3Ј; IL-1β-AS 5Ј-AGAAGGTGCTCATGTCC-TCA-3Ј; IL-6-S 5Ј-GTTCTCTGGGAAATCGTGGA-3Ј; IL-6-AS 5Ј-TGTACTCCAGGTAGCTATGG-3Ј; IFN-γ-S 5Ј-GCTCTGAG-ACAATGAACGCT-3Ј; IFN-γ-AS 5Ј-AAAGAGATAATCTGGCT-CTGC-3Ј; IL-2-S 5Ј-GACACTTGTGCTCCTTGTCA-3Ј; IL-2-AS 5Ј-TCAATTCTGTGGCCTGCTTG-3Ј; IL-4-S 5Ј-TCGGCATTTT-GAACGAGGTC-3Ј; IL-4-AS 5Ј-GAAAAGCCCGAAAGAGTC-TC-3Ј; TNF-α-S 5Ј-TCTCATCAGTTCTATGGCCC-3Ј; TNF-α-AS 5Ј-GGGAGTAGACAAGGTACAAC-3Ј; TGF-β1-S 5Ј-ACCG-CAACAACGCCATCTAT-3Ј; TGF-β1-AS 5Ј-GTAACGCCAGG-AATTGTTGC-3Ј (27) . The reaction mixture was prepared as a master mixture to minimize variations. Aliquots were then amplified by 35 cycles in a GeneAmp 9600 DNA thermocycler (Perkin-Elmer, Irvine, CA). Each cycle consisted of denaturation at 94°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 30 s. The detection limit of the mRNA molecules was 10 2 -10 3 molecules at 35 cycles of PCR when visualized by ethidium bromide staining with all the primers used in this study. An aliquot of PCR product was then electrophoresed on 2% agarose gel and visualized by ethidium bromide staining. Negative controls included amplification of reaction buffer alone and amplification of total RNA that had not been reverse transcribed.
Semi-quantitative PCR
Samples were compared by competitive PCR using primers specific for β 2 m with a fixed amount of target cDNA plus serially diluted 4-fold competitor DNA. This competitor (plasmid pMus) consisted of 5Ј and 3Ј primer sequences in tandem array, and was generously provided by D. Shire (Sanofi Bioreserches, Labè ge, France) (27) . Target and control cDNA competed for the primers during co-amplification so that the amount of PCR product was proportional to the amount of input cDNA. Cytokine mRNA levels was determined by PCR for 35 cycles on normalized cDNA. Cytokine mRNA levels onto the different mouse livers or tumor cell lines were compared by analyzing all the samples during the same cytokine cDNA amplification procedure. The cytokine PCR products were quantified using an imaging system (Visiomic; Genomic, Collonges sous Saleve, France). Gels were scanned and the fluorescence of the ethidium bromide bound to PCR products in each lane was automatically determined. The relative intensity of individual bands on a given gel was used as indicator of cytokine mRNA amounts.
Statistical analysis
Randomized variance analysis (ANOVA) was used within the various groups of mice to determine whether the cytokine mRNA production varied significantly during the tumor development. Subgroups of ASV-B mice were compared to the control population using Student's t-test. Results are presented as means Ϯ SEM for the indicated number of mice. Calculations were done using StatView software (Abacus Concepts, Berkeley, CA) and statistical significance was assessed at the 95% confidence level.
Results
Tumor growth during the development of HCC in ASV-B transgenic mice
In order to record alterations in the macroscopic tumor growth during the development of HCC, the liver/total body weight ratio was measured every 14 days from birth to death in ASV-B mice (Fig. 1 ). There were three distinct phases of tumor growth in vivo during the development of HCC. During the first phase (Ͻ100 days of age), the liver size in ASV-B mice and control mice increased at the same rate. The liver size increased markedly in ASV-B mice in the second phase (100-170 days) and grew slower during the third phase (Ͼ170 days). The weight of the fully developed HCC was at least 6 times that of a normal liver.
IL-1α, IL-1β, IL-6, IFN-γ, TNF-α, TGF-β1, IL-2 and IL-4 mRNA production over the course of HCC in ASV-B transgenic mice
The course of tumor development in ASV-B mice was analyzed for appearance or changes in cytokine mRNA patterns in the liver. The production of IL-2, IL-4 and IFN-γ mRNA was examined, since these mainly T cell-derived products are markers of an immune response which may be involved in the control of tumor development. The expression of the proinflammatory cytokines IL-1α, IL-1β, IL-6, TNF-α and TGF-β1 mRNA was also assessed. These cytokines are involved in the control of cell growth and are potential regulators of hepatocytes activation. The sequential production of cytokines mRNA during tumor growth was monitored using a semiquantitative RT-PCR system in a total of 45 ASV-B mice and 15 non-transgenic female mice (control mice), from the same litter and bred in the same facilities.
Neither IL-2 nor IL-4 transcripts were detectable in liver samples from ASV-B or control mice (Fig. 2) . IFN-γ mRNA expression was barely detectable in only three of 45 liver samples from ASV-B mice, thus its sporadic expression was not considered significant. IL-1β mRNA was detected in Ͼ85% of samples from ASV-B mice as well as control mice and the expression of these transcripts was not significantly altered during HCC in the ASV-B mice when compared to control mice. IL-1α mRNA was detected in more than half of liver samples from ASV-B and control mice, but varied independently from age. IL-6 mRNA was undetectable throughout the HCC. Since RNAs encoding IL-2, IL-4 and IL-6 cytokines were never detected in vivo in the liver of the ASV-B or control mice, we checked that i.v. administration of 400 µg concanavalin A to the control mice resulted in T cell activation-associated hepatic injury (28) . Within 2 h after injection of concanavalin A, RT-PCR of RNA from livers of treated mice resulted in amplification of IL-1α, IL-1β, IL-2, IL-4, IL-6, IFN-γ and TNF-α mRNA, but not TGF-β mRNA (Fig. 2) .
In contrast, levels of TNF-α and TGF-β1 mRNA in certain liver samples from ASV-B mice were significantly elevated, while 14 of the 15 control animals (aged 1-7 months) had barely detectable levels of these mRNA in the liver. The production of TNF-α transcripts could be detected in 14 of 20 liver samples from ASV-B mice younger than 100 days and in seven of 25 samples from older mice. According to the ANOVA F-test, the amounts of TNF-α mRNA in the liver of ASV-B mice varied significantly during tumor development (P Ͻ 0.005). The expression level of TNF-α transcripts was maximal in ASV-B mice aged 60-90 days (14 times the control level, P Ͻ 0.002). Mice aged 90-120 days had lower expression of TNF-α transcripts but it remained higher than in control mice (9 times the control level, P Ͻ 0.01). Eventually, most of ASV-B mice younger than 60 days and older than 120 days had no significantly elevated amounts of TNF-α mRNA in their liver (Fig. 3a) .
Almost all (15 of 16) ASV-B mice younger than 90 days had a basal expression of TGF-β1 mRNA, while nine of 29 older mice displayed high hepatic levels of this transcript. However, according to the ANOVA F-test, variations of TGF-β1 mRNA in the liver of ASV-B mice were not statistically significant. The amount of TGF-β1 mRNA in the liver of ASV-B mice over . Total liver RNA (2 µg) from each mouse were reverse transcribed to cDNA and competitive PCR was performed to obtain the equivalent amounts of ubiquitous β 2 m cDNA. cDNA (100 ng) was amplified by PCR using specific primers to detect the indicated cytokine or β 2 m cDNA. An aliquot (40%) of the PCR-amplified material was separated by electrophoresis on ethidium bromide-stained agarose gels and the PCR products were visualized under UV light.
90 days of age varied greatly and may be responsible for the failure of the ANOVA F-test. Nevertheless, the level of TGF-β1 transcripts in transgenic mice aged 90-120 days was more elevated than in the control mice (7 times the control level, P Ͻ 0.043) (Fig. 3b) . Analysis of the whole population at the individual level revealed that liver samples from ASV-B mice with the higher levels of TNF-α mRNA (mainly 60-90 days mice) all had a basal expression of TGF-β1 mRNA. In contrast, most of the liver samples with high levels of TGF-β1 mRNA (mice older than 90 days) had low or medium levels of TNF-α mRNA (data not shown). This suggests that there are non-exclusive but distinct patterns of TNF-α and TGF-β1 gene expression during HCC within the hepatic population, in the absence of involvement of the other cytokines studied. Fig. 3 . Kinetic of TNF-α and TGF-β1 mRNA production in the liver of 45 ASV-B mice during HCC and 15 control mice, as assessed by semi-quantitative RT-PCR. Total liver RNA (2 mg) from each mouse was reverse transcribed to cDNA and competitive PCR was performed to obtain the equivalent amounts of ubiquitous β 2 m cDNA. cDNA (100 ng) was used in PCR to detect the indicated cytokine mRNA. The relative amounts of cytokine mRNA expression were compared by pooling all liver cDNA samples for PCR amplification of cytokine transcripts. An aliquot (40%) of the PCR-amplified material was separated by electrophoresis on ethidium bromide-stained agarose gels and the amount of PCR products was determined by scanning gels. The figure shows the relative amounts of (a) TNF-α and (b) TGF-β1 mRNA. The data are expressed as the means Ϯ SEM for each subgroup of ASV-B mice (30-60, 60-90, 90-120, 120-150 and 150-215 days) or the control mice subgroup. The subgroups of ASV-B mice and the control population were compared by using Student's t-test, and statistical significance of these comparisons is reported on bars.
TNF-α and TGF-β1 mRNA production in tumor cell lines from ATIII-TSV40 transgenic mice
Tumor cells can produce cytokines during tumor development that may regulate their phenotype, particularly their growth (9) . To evaluate the contribution of hepatocytes in the production of cytokine mRNA observed in vivo, isolated hepatocyte tumor cells derived from two stages of HCC in transgenic mice were used. A first group of cell lines included ATF7 cells derived from a 90-day-old ASV-B mouse, at an early stage of tumor development when only small delimited tumoral nodules (~1 mm diameter) were detected. A second group of cell lines included AT1-F8, AT2 and AT3-F hepatocyte-like cell lines. They were established when the HCC was fully developed from 6-month-old transgenic mice carrying the same ATIII-TSV40 transgene, as previously described (24, 25) .
The tumor cells were tested for their production of the growth factors TNF-α and TGF-β1 mRNA by RT-PCR (Fig. 4) . Cells of the B lymphoma A20 line and the T lymphoma EL4 line, which are known to produce TNF-α or TGF-β1 mRNA respectively (7, 29) , were included as positive controls. The four hepatocyte-like cell lines produced exclusive patterns of TNF-α or TGF-β1 mRNA. TNF-α mRNA was produced by ATF7 cells, whereas AT1-F8, AT2 and AT3-F cells all produced no detectable amounts of TNF-α mRNA. TGF-β1 mRNA was significantly produced by AT1-F8, AT2 and AT3-F cells. Conversely, TGF-β1 transcripts were barely detectable in ATF7 cells. Eventually, the expression of other cytokine mRNAs such as IL-1α, IL-1β, IL-6, IFN-γ, IL-2 and IL-4 was not detectable in any of the four hepatocytes tumor cell lines (data not shown).
Effects of TNF-α and TGF-β1 on the growth of tumor cell lines
The patterns of TNF-α and TGF-β1 gene expression in vivo and in vitro were markedly modified during tumor development in ASV-B mice. In vivo, a change in the pattern of TNF-α and TGF-β1 mRNA correlated with the macroscopic increase of the liver size. This suggested a possible regulation of tumor cell growth by these two autologous or heterologous cytokines. The regulation of tumor cell growth was investigated in vitro by examining hepatocyte tumor cell lines established at early (ATF7 cells) or late (AT1-F8, AT2 and AT3-F cells) stages of tumor progression for their sensitivity to TNF-α and TGF-β1. Tumor cells were exposed to various doses of recombinant TNF-α and TGF-β1, and their sensitivities to these growth factors were assessed by measuring the remaining viable cells, as determined by the MTT test.
TGF-β1 induced different responses on tumor cell lines (Fig. 5a ). The growth of ATF7 cells was profoundly reduced in the presence of TGF-β1, showing a plateau of 85% of growth inhibition with a dose of 2 U/ml in 72 h assays. By contrast, the growth of AT1-F8 cells was less strongly inhibited (50% growth inhibition at 4 U/ml of TGF-β1), while AT2 and AT3-F cells were not significantly sensitive to the growth inhibitory effect of TGF-β1.
On the contrary, TNF-α did not significantly alter the growth of any of the four tumor cell lines, even at the highest concentration of 50 ng/ml in a 72 h cytotoxic assay (Fig. 5b) . Controls included the WEHI-164/13 murine fibrosarcoma cell line, which is highly sensitive to TNF-α (79% growth inhibition at 3.1 ng/ml). The resistance to TNF-α was further investigated on hepatocyte cell lines in the presence of ActD (100-300 ng/ml), which inhibits transcription (12) . ActD alone inhibited the growth of all the four tumor cell lines, even at the low dose of 30 ng/ml (data not shown). All cell lines were sensitive to TNF-α with a dose of 300 ng/ml ActD in 24 h cytotoxic assays (45-30% growth inhibition at 50 ng/ml TNF-α) (Fig. 5c ). Although this sensitivity appears only moderately, it is clearly dose dependent. AT1-F8, AT2 and AT3-F cells gave confirmatory results in 48 or 72 h cytotoxic assays, but unfortunately the susceptibility of ATF7 cells could not be evaluated in these assays since these cells were killed by 100 or 300 ng/ml ActD alone (data not shown).
TNF-α-mediated cytotoxicity for AT1-F8, AT3-F and ATF7 cells was also induced by IFN-γ (Fig. 6a,c,d ). Their growth was inhibited of 60% for AT3-F cells and 55% for ATF7 cells and only 25% for AT1-F8 cells by 30 U/ml IFN-γ plus 10 ng/ ml TNF-α, compared to IFN-γ alone in 48 h assays. However, with doses of IFN-γ Ͼ1 U/ml, the growth of AT2 cells was not significantly affected by the combination of IFN-γ and TNF-α (Fig. 6b) .
Discussion
In this study, we explored the cytokine-driven modulation of tumor growth in a developing HCC in transgenic mice harboring the SV40-T oncogene in the liver. The course of HCC development was characterized by a non-uniform kinetic of macroscopic tumor growth in the ASV-B transgenic mice. A unique phase of tumor growth started after the age of 100 days. As the expression SV40-T transgene is detectable since the perinatal stage (21), the macroscopic development of the liver tumor is obviously delayed when compared to the kinetic of the expression of the oncogene. The production of various cytokines mRNA was assessed in vivo over the course of HCC to further assess the regulation of tumor growth. We analyzed cytokines belonging to tumor growth factors, proinflammatory cytokines or T cell-derived products. In this study, no particular alteration of IL-1α, IL-1β, IL-6, IFN-γ, IL-2 and IL-4 mRNA production could be observed during HCC development. Thus, the HCC development appears to be not associated with liver infiltration induced by tumor-associated inflammatory cells that could have regulated the activation of hepatocytes in the transgenic mice. These observations are consistent with the poor lymphocyte infitrate observed in liver sections during HCC progression (21) and the absence of a spontaneous antitumor-specific immune response in the transgenic mice (R. Romieu et al., in preparation). Preliminary studies suggest that HCC development in the transgenic mice is not associated with the induction of Fas ligand production (unpublished results), the involvement of which in tumor growth regulation has been recently suggested in human HCC (30) .
Conversely, the patterns of TNF-α and TGF-β1 mRNA, which belong to both proinflammatory and tumor-specific cytokines, markedly changed in vivo during HCC progression. The greatest amounts of TNF-α mRNA were detected early in tumor development in ASV-B mice (days 60-90), before the macroscopic increase in tumoral liver size. The amounts of TNF-α transcripts gradually decreased thereafter. Conversely, TGF-β1 gene expression was never detected before the onset of the macroscopic tumor growth phase. TGF-β1 transcripts were significantly produced in the livers of ASV-B mice aged over 90 days, when compared to control mice. The great variations in the amounts of TGF-β1 transcripts in ASV-B mice aged Ͼ120 days could be due to several factors, including the heterogeneity of cells within the tumor mass at the end of HCC. Further studies on ASV-B mice aged Ͼ120 days revealed only minor differences in hepatic cytokine mRNA patterns for a single animal (data not shown). Altogether, these results suggest that activated transcription of TNF-α and TGF-β1 genes may be associated with the hepatocarcinogenesis and particularly with changes in tumor growth in the transgenic mice. Interestingly, an increased expression of TGF-β in human HCC has been reported (31). However, very few studies have examined the relationship between the production of cytokines in the tumor and tumor stages in vivo. Recently, Van Belle et al. reported an in situ increase of the three isoforms of TGF-β from primary to metastatic human melanomas, which suggested that the production of TGF-β is associated with tumor progression in these cancers (18) .
The tumor-derived cell lines from transgenic mice proved to be useful tools with which to analyze the tumorigenic process in vitro. We showed here that tumor cell lines established from transgenic mice at two stages of HCC, either before or after HCC differentiation, displayed opposite phenotypes that differed in their ability to produce TNF-α and TGF-β1 mRNA. One of these cell lines, ATF7 cells, derived from a 90-day-old ASV-B mouse, just before the increase of the tumor size, produced TNF-α mRNA but had barely detectable levels of TGF-β1 mRNA. Three other cell lines, AT1-F8, AT2 and AT3-F cells, were established from 6-monthold transgenic mice (ATIII-TSV40), corresponding to the fully developed HCC (24, 25) . These cell lines produced no TNF-α mRNA, but did contain TGF-β1 mRNA. Although tissue culture conditions can alter the phenotype of tumor cells, particularly for the production of growth modulators like TGF-β (32), the sequential increase in the expression of TNF-α and TGF-β1 mRNA in liver extracts from transgenic mice over the course of HCC appeared to parallel those monitored in vitro on tumor cell lines. The exact source of TNF-α and TGF-β1 in HCC in vivo remains to be defined, but this suggests that hepatocyte tumor cells may be a source of these cytokines. We are currently investigating the production of intracellular, secreted or membraneous forms of TNF-α and TGF-β by tumor cell lines. Preliminary studies indicate that hepatocyte tumor cells do not all release active forms of TGF-β as assessed by bioassay (data not shown).
These results led us to investigate the modulation of tumor cell growth regulation by TNF-α and TGF-β1, which are the sole cytokines affected during the course of HCC development in this study. The susceptibility to TNF-α and TGF-β1 of the hepatocyte tumor cell lines was evaluated in vitro by measuring cell viability (as a result of cell proliferation and death) after exposure to these cytokines. None of the four hepatocyte tumor cell lines was sensitive to TNF-α. Nevertheless, most tumor and normal cell lines are refractory to the cytotoxic action of TNF-α (11). The nature of TNF-α resistance was explored by incubating tumor cell lines with ActD, an inhibitor of transcription. All the tumor cell lines were susceptible to the cytotoxic effect of TNF-α when incubated with ActD. It has been suggested that the ActD-dependent susceptibility is linked to decreased synthesis of proteins that inhibit the response to TNF-α (12, 33) . The ActD effects strongly suggest that all the hepatocyte cell lines studied bear p55 and/or p75 TNF receptors. Furthermore, the ATF7, AT1-F8 and AT3-F cells could be made susceptible to TNF-α by IFN-γ, but AT2 cells could not. IFN-γ may enhance the production of TNF receptors (34) . Nevertheless, these observations suggest that the resistance of hepatocyte tumor cell lines to TNF-α is not directly correlated with the production of TNF-α mRNA. Interestingly, such a correlation between cell resistance to TNF-α and expression of the TNF-α gene has been previously described in a human breast tumor cell line (19) .
However, early-and late-stage hepatocyte tumor cell lines had different susceptibilities to TGF-β1. The early-stagederived cell line ATF7 was sensitive to the growth inhibitory effects of TGF-β1 (90% growth inhibition), while late-stagederived cell lines AT1-F8, AT2 and AT3-F displayed a loss of sensitivity to TGF-β1 (25-50% growth inhibition). Acquired resistance to TGF-β has been described as a marker of progression towards tumorigenicity in other in vitro models of tumor cells (15, 35) . Many factors could be involved in the modulation of sensitivity to TGF-β. Particularly, SV40 transforming proteins, like other DNA virus proteins, may abrogate sensitivity to growth factors, including TGF-β (36) . Nevertheless, in this study there appeared to be no correlation between the sensitivity to TGF-β1 of hepatocyte tumor cells and the level of SV40-T protein production, as assessed by indirect immunofluorescence (V. Lacabanne et al., in preparation). On the contrary, the resistance to TGF-β1 of the four tumor cell lines paralleled the expression of TGF-β1 mRNA. Several reports have shown that intracellular or secreted cytokines may act as growth modulators for tumor cells (3, 19) . Altogether, these observations suggest a possible autocrine regulation of cell growth during HCC. The endogenous TGF-β may indirectly stimulate tumor growth by promoting angiogenesis and stroma development, as was recently reported for human HCC (37) . This soluble factor may also contribute to immune dysregulation and immunosuppression (38) , either locally in the tumor or at distant sites in lymphoid organs, thus favoring tumor growth. In this context, the liver-directed expression of SV40-T oncogene in the ASV-B transgenic mice could be a valuable model for assessing in vitro and in vivo the mechanisms involved in cytokine-regulation of tumor growth. The impact of various therapeutic strategies designed to circumvent tumor growth, including such promising protocols as immunointervention, should also be envisaged in this HCC model.
